Oppenheimer set a $9.00 price target on Evofem Biosciences (NASDAQ:EVFM) in a research report sent to investors on Friday, November 16th. The brokerage currently has a buy rating on the biotechnology company’s stock.

A number of other equities research analysts have also recently weighed in on EVFM. Cantor Fitzgerald reiterated a buy rating and set a $9.00 price target on shares of Evofem Biosciences in a research report on Thursday, November 15th. ValuEngine upgraded shares of Evofem Biosciences from a hold rating to a buy rating in a report on Thursday, November 1st. Finally, HC Wainwright set a $11.00 price objective on shares of Evofem Biosciences and gave the company a buy rating in a report on Monday, August 6th. Six equities research analysts have rated the stock with a buy rating, Evofem Biosciences presently has an average rating of Buy and an average price target of $10.40.

EVFM stock traded down $0.34 during trading on Friday, reaching $3.54. 11,377 shares of the stock were exchanged, compared to its average volume of 17,752. Evofem Biosciences has a 1 year low of $1.79 and a 1 year high of $12.90.

Evofem Biosciences (NASDAQ:EVFM) last issued its earnings results on Wednesday, November 7th. The biotechnology company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.34). On average, research analysts anticipate that Evofem Biosciences will post -5.8 EPS for the current fiscal year.

Several large investors have recently modified their holdings of the company. Woodford Investment Management Ltd lifted its position in shares of Evofem Biosciences by 28.5% during the 2nd quarter. Woodford Investment Management Ltd now owns 9,593,197 shares of the biotechnology company’s stock worth $25,998,000 after buying an additional 2,127,659 shares during the last quarter. Millennium Management LLC lifted its position in shares of Evofem Biosciences by 6,497.4% during the 2nd quarter. Millennium Management LLC now owns 733,765 shares of the biotechnology company’s stock worth $1,989,000 after buying an additional 722,643 shares during the last quarter. Heartland Advisors Inc. purchased a new stake in shares of Evofem Biosciences during the 3rd quarter worth approximately $1,319,000. Finally, Vanguard Group Inc. purchased a new stake in shares of Evofem Biosciences during the 3rd quarter worth approximately $879,000. Institutional investors and hedge funds own 77.81% of the company’s stock.

Evofem Biosciences Company Profile

Evofem Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. Its lead product candidate is Amphora that is in Phase 3 trial for contraception; and in Phase 2b/3 clinical trial for prevention of chlamydia and gonorrhea in women.

See Also: Preferred Stock

Analyst Recommendations for Evofem Biosciences (NASDAQ:EVFM)

Receive News & Ratings for Evofem Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evofem Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.